US-based wearable tech company Enable Injections has confirmed plans to expand to a 90,000ft² manufacturing center as it looks to expand its Cincinnati headquarters.
The company said that the expansion will help boost production of its EnFuse wearable injector device which is designed to discretely deliver medicine to patients throughout the day.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Enable Injections has said it is the first-ever hands-free wearable technology that allows patients to self-administer large-volume medications subcutaneously without an IV or syringe pump.
The wearable injector, sold in the US by Apellis Pharmaceuticals, was granted market clearance by the US Food and Drug Administration in October 2023 for the subcutaneous delivery of Empaveli (pegcetacoplan) for adults with paroxysmal nocturnal hemoglobinuria (PNH)
Mike Hooven, chairman and CEO of Enable Injections, said: “Scalable, in-house manufacturing is a key pillar of Enable’s strategy to accelerate the supply of our innovative EnFuse technology as the company continues to grow our roster and scope of clinical and commercial engagements with pharmaceutical partners.
“This new facility allows Enable to significantly expand and enhance production processes and ultimately reduce the time it takes to bring our enFuse system to patients and the medical community.”
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataEnable expects to move into the new manufacturing centre by the end of this year and that the expansion will allow the company to retain workers and add as many as 450 jobs to its potential workforce over the next ten years. At the same time, the company has said that it will also be renovating the infrastructure of its Evendale headquarters.
While Apellis Pharmaceuticals claims that in 2022 Empaveli generated $65.1m in sales, it is not the only treatment for PNH that is delivered by intravenous infusion. Ultomiris (ravulizumab) marketed by Alexion Pharmaceuticals, generated $1.96bn in sales itself in 2022. GlobalData’s Medical Device Intelligence Centre estimates that the market value of Empaveli is expected to exceed $2bn by 2030.
Hooven added: “We are proud to have grown our business in Ohio over the last decade and are thankful for the continued support from the state and local organizations as we expand our business operations and footprint.”
Elsewhere in the field of medical device manufacturing Molex has announced plans to open a new 23,000m² facility in Poland to significantly expand its medical device output for Phillips-Medisize.
